Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

Journal of Anxiety Disorders

Volumn 23, Issue 3, 2009, Pages 362-368

  Donahue, Christopher B ^a   Kushner, Matt G ^a   Thuras, Paul D ^a   Murphy, Tom G ^a   Van Demark, Joani B ^a   Adson, David E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Public speaking; Quetiapine; Social anxiety; Social phobia; Virtual reality

Indexed keywords

ANTIPSYCHOTIC AGENTS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; MALE; PHOBIC DISORDERS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPEECH; USER-COMPUTER INTERFACE; YOUNG ADULT;

EID: 60749092744     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.janxdis.2008.12.004     Document Type: Article

References (50)

1. Adson D.E., Kushner M.G., Eiben K.M., and Schulz S.C. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 19 2 (2004) 121-126
2. Alpers G.W., Abelson J.L., Wilhelm F.H., and Roth W.T. Salivary cortisol response during exposure treatment in driving phobics. Psychosomatic Medicine 65 4 (2003) 679-687
3. Altmaier E., Ross S., Leary M., and Thornbrough M. Matching stress inoculation's treatment components to clients' anxiety mode. Journal of Counseling Psychology 29 (1982) 331-334
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
5. Bandelow, B., Bobes, J., Ahohas, A., Eggens, I., Liu, S., & Brecher, M. (2007). Results from a phase ii study of once-daily extended release quitiapine fumarate (quitiapine xr) monotherapy in patients with generalized anxiety disorder. Paper presented at the international forum on mood and anxiety disorders, Budapest, Hungary.
6. Bauer, M., Pretorius, H. W., Earley, W., Lindgren, P., & Brecher, M. (2007). Results from a phase ii study of extended release quitiapine fumarate (quetiapine xr) as add-on to antidepressants in patients with major depressive. Paper presented at the international forum on mood and anxiety disorders, Budapest, Hungary.
7. Beck A.T., Steer R.A., and Garbin M. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clinical Psychology Review 8 (1988) 77-100
8. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 4 (1961) 561-571
9. Brawman-Mintzer, O. (2006). Quetaipine monotherapy in patients with generalized anxiety disorder. Abstract 341. A flexible dose, open-label trial evaluating the efficacy and safety of quetiapine (quetiapine) as adjunctive pharmacotherapy for the treatment of generalized anxiety disorder (gad). Paper presented at the 26th annual conference of the Anxiety Disorders Association of America (ADAA), Miami, Florida.
10. Calabrese, J. R. e. a. (2004). Quetiapine effective against anxiety in bipolar depression. Paper presented at the annual meeting of the American Psychiatric Association, New York.
11. Carrigan M.H., and Levis D.J. The contributions of eye movements to the efficacy of brief exposure treatment for reducing fear of public speaking. Journal of Anxiety Disorders 13 1-2 (1999) 101-118
12. Clark D.M., Ehlers A., McManus F., Hackmann A., Fennell M., Campbell H., et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. Journal of Consulting and Clinical Psychology 71 6 (2003) 1058-1067
13. Cohrs S., Rodenbeck A., Guan Z., Pohlmann K., Jordan W., Meier A., et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berlin) 174 3 (2004) 421-429
14. Cornwell B.R., Johnson L., Berardi L., and Grillon C. Anticipation of public speaking in virtual reality reveals a relationship between trait social anxiety and startle reactivity. Biological Psychiatry 59 7 (2006) 664-666
15. Daly J. The assessment of social-communicative anxiety via self-reports: a comparison of measures. Communcation Monographs 45 (1978) 204-218
16. Davidson J.R.T., Fos E.B., Huppert J.D., Keefe F., Franklin M., Compton J., et al. Fluoxetine, comprehensive cbt and placebo in generalized social phobia. Archives of General Psychiatry 13 (2004) 423-428
17. de Borja Goncalves Guerra A., Castel S., Benedito-Silva A.A., and Calil H.M. Neuroendocrine effects of quetiapine in healthy volunteers. International Journal of Neuropsychopharmacology 8 1 (2005) 49-57
18. Difede J., Cukor J., Jayasinghe N., Patt I., Jedel S., Spielman L., et al. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. Journal of Clinical Psychiatry 68 11 (2007) 1639-1647
19. Fava G.A., Grandi S., Rafanelli C., Ruini C., Conti S., and Belluardo P. Long-term outcome of social phobia treated by exposure. Psychological Medicine 31 5 (2001) 899-905
20. First M.B., Gibbon M., Williams J.B.W., and Spitzer R.L. Mini-skid (1990), Multi-Health Systems, Inc.
21. Fresco D.M., Coles M.E., Heimberg R.G., Liebowitz M.R., Hami S., Stein M.B., et al. The Liebowitz social anxiety scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychological Medicine 31 6 (2001) 1025-1035
22. Freske U., and Chambless D.L. Cognitive-behavioral vs. exposure only treatments for social phobia. Behavior Therapy 26 (1995) 695-720
23. Gelernter C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Archives of General Psychiatry 48 10 (1991) 938-945
24. Gould R.A., Buckminster S., Pollack M.H., Otto M.W., and Yap L. Cognitive-behavioral and pharmacological treatment of social phobia: a meta-analysis. Clinical Psychology and Scientific Practice 4 (1977) 291-306
25. Grant B.F., Hasin D.S., Blanco C., Stinson F.S., Chou S.P., Goldstein R.B., et al. The epidemiology of social anxiety disorder in the United States: results from the national epidemiologic survey on alcohol and related conditions. Journal of Clinical Psychiatry 66 11 (2005) 1351-1361
26. Heimberg R.G., Horner K.J., Juster H.R., Safren S.A., Brown E.J., Schneier F.R., et al. Psychometric properties of the liebowitz social anxiety scale. Psychological Medicine 29 1 (1999) 199-212
27. Hoddes E., Dement W.C., and Zarcone V. The development and use of the Stanford sleepiness scale (sss). Psychophysiology 10 (1973) 431-436
28. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Archives of General Psychiatry 63 3 (2006) 298-304
29. Jones G., Phillips G., and Rieger E. Effects of cardiac awareness, public speaking anxiety, and physiological "priming" on state-trait anxiety (state) and feelings of apprehension. Psychophysiology 32 Suppl. (1995) S43
30. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of dsm-iii-r psychiatric disorders in the United States. Results from the national comorbidity survey. Archives of General Psychiatry 51 1 (1994) 8-19
31. Kinrys, G., Nery, F., Vasconcelos, D., Rothstein, E., Dunn, R., Bianco, R., et al. (2007). Quetiapine augmentation of ssris for treatment refractory of social anxiety disorder (sad). Paper presented at the Poster presented at the 2th European College of Neuropsychopharmacology, Vienna Austria.
32. Liebowitz M.R. Social phobia. Modern Problems of Pharmacopsychiatry 22 (1987) 141-173
33. Mannuzza S., Schneier F.R., Chapman T.F., Liebowitz M.R., Klein D.F., and Fyer A.J. Generalized social phobia Reliability and validity. Archives of General Psychiatry 52 3 (1995) 230-237
34. Margolese H.C., Chouinard G., Beauclair L., and Belanger M.C. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology 22 (2002) 347-352
35. Marton P., Churchard M., Kutcher S., and Korenblum M. Diagnostic utility of the beck depression inventory with adolescent psychiatric outpatients and inpatients. Canadian Journal of Psychiatry 36 6 (1991) 428-431
36. Montgomery, S., Cutler, A., Lazarus, A., Schollin, M., & Brecher, M. (2007). A randomized, placebo-controlled study of once-daily extended release quetiapine fumarate (quitiapine xr) monotherapy in patients with major depressive disorder (mdd). Paper presented at the international forum on mood and anxiety disorders, Budapest, Hungary.
37. Nejtek V.A. High and low emotion events influence emotional stress perceptions and are associated with salivary cortisol response changes in a consecutive stress paradigm. Psychoneuroendocrinology 27 3 (2002) 337-352
38. Paul G. Insights vs. desensitization in psychotherapy (1966), Stanford University Press, Stanford
39. Pertaub D., Slater M., and Barker C. An experiment on public speaking anxiety in response to three different types of virtual audience. Presence: Teleoperators and Virtual Environments 11 (2002) 68-78
40. Philip N.S., Mello K., Carpenter L.L., Tyrka A.R., and Price L.H. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Annals of Clinical Psychiatry 20 1 (2008) 15-20
41. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry 61 11 (2004) 1136-1144
42. Rowe D.L. Off-label prescription of quetiapine in psychiatric disorders. Expert Review of Neurotherapeuties 7 7 (2007) 841-852
43. Schuler K., Gilner F., Austrin H., and Davenport D.G. Contribution of the education phase to stress-inoculation training. Psychological Reports 51 2 (1982) 611-617
44. Schutters S.I., van Megen H.J., and Westenberg H.G. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. Journal of Clinical Psychiatry 66 4 (2005) 540-542
45. Slater M., Pertaub D.P., Barker C., and Clark D.M. An experimental study on fear of public speaking using a virtual environment. Cyberpsychology and Behavior 9 5 (2006) 627-633
46. Stein M.B., Walker J.R., and Forde D.R. Public-speaking fears in a community sample. Prevalence, impact on functioning, and diagnostic classification. Archives of General Psychiatry 53 2 (1996) 169-174
47. Tarico V., van Velzen D., and Altmaier E. Comparison of thought-listing rating methods. Journal of Counseling Psychology 31 (1986) 81-83
48. Tillfors M., and Furmark T. Social phobia in Swedish university students: prevalence, subgroups and avoidant behavior. Social Psychiatry and Psychiatric Epidemiology 42 1 (2007) 79-86
49. Turner S.M., Beidel D.C., and Jacob R.G. Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting and Clinical Psychology 62 2 (1994) 350-358
50. Vaishnavi S., Alamy S., Zhang W., Connor K.M., and Davidson J.R. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Progress in Neuropsychopharmacology and Biological Psychiatry 31 7 (2007) 1464-1469